SPY330.30+3.33 1.02%
DIA272.81+1.37 0.50%
IXIC10,963.64+184.84 1.71%

Viking Therapeutics Highlights Presentation Of New Data From Phase 2 Study Of VK2809 In Patients With Non-Alcoholic Fatty Liver Disease And Elevated LDL-Cholesterol At The Digital International Liver Congress 2020

VK2809-Treated Patients Maintain Durable, Statistically Significant Liver Fat Reductions at Week 16, Four Weeks Following Last Study Dose Significant Reductions in Week 12 Liver Fat Content Achieved Across Spectrum of

 · 

VK2809-Treated Patients Maintain Durable, Statistically Significant Liver Fat Reductions at Week 16, Four Weeks Following Last Study Dose
Significant Reductions in Week 12 Liver Fat Content Achieved Across Spectrum of Baseline Characteristics and Common NASH Risk Factors

SAN DIEGO, Aug. 28, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the presentation of new results from the company's 12-week Phase 2 study of VK2809 in patients with non-alcoholic fatty liver disease (NAFLD) and elevated low-density lipoprotein cholesterol (LDL-C) at the Digital International Liver Congress™ 2020. The study results were featured in an oral presentation at the annual meeting of the European Association for the Study of the Liver (EASL), being held virtually August 27-29, 2020.